COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
08 déc. 2022 04h00 HE
|
COMPASS Pathways
12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II...
COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference
28 nov. 2022 16h01 HE
|
COMPASS Pathways
LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
03 nov. 2022 07h00 HE
|
COMPASS Pathways
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Highlights: Phase 3 pivotal program design finalized and on track to start in 2022; several clinical sites have been initiatedPhase 2b trial data...
COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine
03 nov. 2022 06h00 HE
|
COMPASS Pathways
After a single 25mg dose of COMP360 psilocybin therapy, approximately 30% of patients with treatment-resistant depression (TRD) were in remission at week 3 Sustained response seen through week...
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
26 oct. 2022 16h00 HE
|
COMPASS Pathways
LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
12 oct. 2022 11h00 HE
|
COMPASS Pathways
LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022
04 oct. 2022 09h05 HE
|
COMPASS Pathways
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit
19 sept. 2022 16h01 HE
|
COMPASS Pathways
LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in three upcoming investor events
01 sept. 2022 08h06 HE
|
COMPASS Pathways
LONDON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
04 août 2022 07h00 HE
|
COMPASS Pathways
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Highlights: Kabir Nath appointed as Chief Executive Officer Phase III program submitted to FDA and under reviewCOMP360 phase II study in...